NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its fiscal fourth quarter revenues rose 8 percent year over year.

For the three months ended June 30, total revenues were $200.5 million, compared to $186.5 million in the year-ago period, and missing the average expectation of Wall Street analysts for revenues of $193.7 million.

Revenues from molecular diagnostic testing were $187.9 million in fiscal Q4, up 8 percent from $173.7 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.